Published in Clin Exp Immunol on September 01, 2006
Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway. Kidney Int (2009) 3.12
Causes of alternative pathway dysregulation in dense deposit disease. Clin J Am Soc Nephrol (2012) 1.70
Characterization of the renal cyst fluid proteome in autosomal dominant polycystic kidney disease (ADPKD) patients. Proteomics Clin Appl (2008) 1.22
Proteomic analysis of electronegative low-density lipoprotein. J Lipid Res (2010) 0.90
Human plasma protein N-glycosylation. Glycoconj J (2015) 0.88
Pathogenic Leptospira species acquire factor H and vitronectin via the surface protein LcpA. Infect Immun (2014) 0.86
Immune complexes and late complement proteins trigger activation of Syk tyrosine kinase in human CD4(+) T cells. Clin Exp Immunol (2012) 0.81
Protein engineering to target complement evasion in cancer. FEBS Lett (2013) 0.80
T cell activation by terminal complex of complement and immune complexes. J Biol Chem (2011) 0.79
Induced expression of FcγRIIIa (CD16a) on CD4+ T cells triggers generation of IFN-γhigh subset. J Biol Chem (2015) 0.79
LRP1b shows restricted expression in human tissues and binds to several extracellular ligands, including fibrinogen and apoE-carrying lipoproteins. Atherosclerosis (2011) 0.78
Dysfunctional High-Density Lipoprotein: An Innovative Target for Proteomics and Lipidomics. Cholesterol (2015) 0.77
Candida albicans Shaving to Profile Human Serum Proteins on Hyphal Surface. Front Microbiol (2015) 0.75
Pain-associated biomarkers in breast cancer. J Med Life (2015) 0.75
Quantitative Modeling of the Alternative Pathway of the Complement System. PLoS One (2016) 0.75
Arg-Gly-Asp: a versatile cell recognition signal. Cell (1986) 7.89
Complete amino acid sequence of human vitronectin deduced from cDNA. Similarity of cell attachment sites in vitronectin and fibronectin. EMBO J (1985) 2.69
SP-40,40, a newly identified normal human serum protein found in the SC5b-9 complex of complement and in the immune deposits in glomerulonephritis. J Clin Invest (1988) 1.90
Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem (1988) 1.77
Incorporation of SP-40,40 into the soluble membrane attack complex (SMAC, SC5b-9) of complement. Int Immunol (1990) 1.57
Extracellular matrix remodeling by human granzyme B via cleavage of vitronectin, fibronectin, and laminin. J Biol Chem (2005) 1.39
Extracellular granzymes A and B in humans: detection of native species during CTL responses in vitro and in vivo. J Immunol (1998) 1.39
Localization of the complement regulatory proteins in the normal human kidney. Kidney Int (1994) 1.37
Complement and apoptosis. Mol Immunol (2001) 1.35
Clusterin is an ATP-independent chaperone with very broad substrate specificity that stabilizes stressed proteins in a folding-competent state. Biochemistry (2000) 1.33
Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. J Clin Invest (2004) 1.31
Complement S-protein (vitronectin) is associated with cytolytic membrane-bound C5b-9 complexes. Clin Exp Immunol (1988) 1.25
The levels of soluble granzyme A and B are elevated in plasma and synovial fluid of patients with rheumatoid arthritis (RA). Clin Exp Immunol (1999) 1.24
Cell signals transduced by complement. Mol Immunol (2004) 1.21
The membrane attack complex of complement induces caspase activation and apoptosis. Eur J Immunol (2002) 1.20
Analysis of the cell infiltrate and expression of matrix metalloproteinases and granzyme B in paired synovial biopsy specimens from the cartilage-pannus junction in patients with RA. Ann Rheum Dis (2001) 1.18
Localization of terminal complement components S-protein and SP-40,40 in renal biopsies. Pathology (1989) 1.17
Localization of the membrane attack complex (MAC) in experimental immune complex glomerulonephritis. J Exp Med (1983) 1.12
Clusterin in renal tissue: preferential localization with the terminal complement complex and immunoglobulin deposits in glomeruli. Clin Exp Immunol (1992) 1.12
Localization and molecular modelling of the membrane-inserted domain of the ninth component of human complement and perforin. Mol Immunol (1990) 1.11
Vitronectin-mediated inhibition of complement: evidence for different binding sites for C5b-7 and C9. Clin Exp Immunol (1993) 1.09
Clusterin, the human apolipoprotein and complement inhibitor, binds to complement C7, C8 beta, and the b domain of C9. J Immunol (1993) 1.08
Heparin-binding properties of vitronectin are linked to complex formation as illustrated by in vitro polymerization and binding to the terminal complement complex. J Biol Chem (1992) 1.08
The cell adhesion domain in plasma vitronectin is cryptic. J Biol Chem (1997) 1.06
The complement SC5b-9 complex mediates cell adhesion through a vitronectin receptor. J Immunol (1990) 1.04
Cytolytically inactive terminal complement complex causes transendothelial migration of polymorphonuclear leukocytes in vitro and in vivo. Blood (2002) 1.00
Comparison between complement and melittin hemolysis: anti-melittin antibodies inhibit complement lysis. Biochemistry (1988) 0.91
SC5b-9 is the most sensitive marker in assessing disease activity in Brazilian SLE patients. J Investig Allergol Clin Immunol (1998) 0.88
Inhibition of terminal complement: a novel therapeutic approach for the treatment of systemic lupus erythematosus. Lupus (2004) 0.85
Immunohistochemical studies of vitronectin, C5b-9, and vitronectin receptor in membranous nephropathy. Nephron (1994) 0.80
Low levels of vitronectin and clusterin in acute meningococcal disease are closely associated with formation of the terminal-complement complex and the vitronectin-thrombin-antithrombin complex. Infect Immun (1994) 0.80
[Terminal complement complex (TCC) levels in urine in patients with renal diseases]. Hokkaido Igaku Zasshi (2001) 0.78
Carcinoembryonic antigen assay in cancer of the colon and pancreas and other digestive tract disorders. Am J Dig Dis (1971) 2.88
Immunologic diagnosis and prognosis of human digestive-tract cancer: carcinoembryonic antigens. N Engl J Med (1972) 2.83
Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. Rheumatology (Oxford) (2005) 2.19
Antiperinuclear factor in juvenile rheumatoid arthritis. Ann Rheum Dis (1992) 1.65
Rheumatoid factor-producing cells detected by direct hemolytic plaque assay. J Clin Invest (1976) 1.62
Mycoplasma infection and rheumatoid arthritis: analysis of their relationship using immunoblotting and an ultrasensitive polymerase chain reaction detection method. Arthritis Rheum (1997) 1.54
CCAAT box binding protein NF-Y facilitates in vivo recruitment of upstream DNA binding transcription factors. EMBO J (1994) 1.53
Dorsal duct sphincterotomy is effective long-term treatment of acute pancreatitis associated with pancreas divisum. Surgery (1989) 1.47
Reduced levels of testosterone and dehydroepiandrosterone sulphate in the serum and synovial fluid of juvenile rheumatoid arthritis patients correlates with disease severity. Clin Exp Rheumatol (1999) 1.46
Sparing of the thumb in Raynaud's phenomenon. Rheumatology (Oxford) (2008) 1.46
Rheumatoid arthritis in the elderly. J Am Geriatr Soc (1991) 1.40
Class II box consensus sequences in the HLA-DR alpha gene: transcriptional function and interaction with nuclear proteins. Mol Cell Biol (1989) 1.24
Carcinoembryonic antigen (CEA) in inflammatory bowel disease. JAMA (1972) 1.23
Normal aging results in decreased synaptic excitation and increased synaptic inhibition of layer 2/3 pyramidal cells in the monkey prefrontal cortex. Neuroscience (2004) 1.21
Functional analysis of c-Myb protein in T-lymphocytic cell lines shows that it trans-activates the c-myc promoter. Mol Cell Biol (1990) 1.20
Major histocompatibility complex class II-associated invariant chain gene expression is up-regulated by cooperative interactions of Sp1 and NF-Y. J Biol Chem (1995) 1.13
Limitation of infarct size in the rabbit by ischaemic preconditioning is reversible with glibenclamide. Cardiovasc Res (1993) 1.08
The in vitro effects of methotrexate on peripheral blood mononuclear cells. Modulation by methyl donors and spermidine. Arthritis Rheum (1990) 1.06
Measurement of biomarkers in juvenile idiopathic arthritis patients and their significant association with disease severity: a comparative study. Clin Exp Rheumatol (2008) 1.03
Heart disease in systemic sclerosis. Semin Arthritis Rheum (1989) 1.02
Cytokine levels in serum and synovial fluid of patients with juvenile rheumatoid arthritis. J Rheumatol (1994) 0.98
Relative reactivities of rheumatoid factors in serum and cells. Evidence for a selective deficiency in serum rheumatoid factor. Arthritis Rheum (1978) 0.97
Extractable nuclear antigens. Semin Arthritis Rheum (1981) 0.97
Antiperinuclear and anti-RA33 antibodies in juvenile chronic arthritis. Ann Rheum Dis (1994) 0.97
Kingella kingae infectious arthritis: case report and review of literature of Kingella and Moraxella infections. Arthritis Rheum (1983) 0.96
Separation and characterization of immune complexes containing 19S IgM rheumatoid factor-IgG in juvenile arthritis. Arthritis Rheum (1983) 0.96
Changing trends in pediatric septic arthritis. Semin Arthritis Rheum (1985) 0.95
Digital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in primary Raynaud's phenomenon and systemic sclerosis. Rheumatology (Oxford) (2002) 0.95
Ehlers-Danlos syndrome presenting as rheumatic manifestations in the child. J Rheumatol (1981) 0.94
Hidden 19S IgM rheumatoid factor in juvenile rheumatoid arthritis. Pediatr Res (1980) 0.93
Differential effects of propranolol on lymphocyte rosette formation and response to plant mitogens. Arthritis Rheum (1978) 0.93
In vitro effects of methotrexate on peripheral blood monocytes: modulation by folinic acid and S-adenosylmethionine. Ann Rheum Dis (1991) 0.93
Immunoprotein deposition in synovial tissue in Reiter's syndrome. Ann Rheum Dis (1981) 0.92
Immune complexes in juvenile rheumatoid arthritis: a comparison of four methods. J Rheumatol (1982) 0.91
Effects of systemic onset juvenile rheumatoid arthritis on facial morphology and temporomandibular joint form and function. J Rheumatol (1996) 0.91
Thrombotic microangiographic hemolytic anemia in systemic lupus erythematosus. Semin Arthritis Rheum (1994) 0.90
Estrogen and progesterone regulation of human fibroblast-like synoviocyte function in vitro: implications in rheumatoid arthritis. J Rheumatol (2000) 0.90
The 'distal-dorsal difference': a thermographic parameter by which to differentiate between primary and secondary Raynaud's phenomenon. Rheumatology (Oxford) (2006) 0.89
C1q-containing immune complexes purified from sera of juvenile rheumatoid arthritis patients mediate IL-8 production by human synoviocytes: role of C1q receptors. J Immunol (1999) 0.89
Clinical response to etanercept in polyarticular course juvenile rheumatoid arthritis. J Rheumatol (2001) 0.89
Prevalence and significance of isotypes of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Ann Rheum Dis (2008) 0.88
Longitudinal study of the presence of hidden 19S IgM rheumatoid factor in juvenile rheumatoid arthritis. J Rheumatol (1982) 0.88
Abnormal microvascular response is localized to the digits in patients with systemic sclerosis. Arthritis Rheum (2006) 0.88
Digital iontophoresis of vasoactive substances as measured by laser Doppler imaging--a non-invasive technique by which to measure microvascular dysfunction in Raynaud's phenomenon. Rheumatology (Oxford) (2004) 0.88
Rheumatoid factors. Clin Chim Acta (1987) 0.88
Vasodilator iontophoresis a possible new therapy for digital ischaemia in systemic sclerosis? Rheumatology (Oxford) (2008) 0.87
Immunologic studies in juvenile arthritis. Bull Rheum Dis (1982) 0.87
Therapeutic use of etanercept in polyarticular course juvenile idiopathic arthritis over a two year period. Ann Rheum Dis (2002) 0.87
The tight-skin mouse: physical and biochemical properties of the skin. J Rheumatol (1983) 0.87
Eosinophilic fasciitis in children. Semin Arthritis Rheum (1989) 0.87
Rheumatoid arthritis in the aged. Incidence and optimal management. Drugs Aging (1994) 0.86
Autoantibodies in juvenile arthritis. Semin Arthritis Rheum (1984) 0.86
Antinuclear antibody in juvenile rheumatoid arthritis sera reacts with 50-40 kDa antigen(s) found in HeLa nuclear extracts. J Rheumatol (1989) 0.86
Effect of methotrexate on the temporomandibular joint and facial morphology in juvenile rheumatoid arthritis patients. Am J Orthod Dentofacial Orthop (2000) 0.86
The B cell-specific nuclear factor OTF-2 positively regulates transcription of the human class II transplantation gene, DRA. J Biol Chem (1992) 0.85
Anticentriole antibody in a patient with progressive systemic sclerosis. Arthritis Rheum (1986) 0.84
Drugs affecting the release of rheumatoid factor in a plaque-forming cell assay. Arthritis Rheum (1978) 0.84
Eosinophilic fasciitis. Semin Arthritis Rheum (1980) 0.84
Acute ethanol and selected growth suppressor transcripts in regenerating rat liver. Alcohol (1995) 0.83
A role for the complement system in rheumatoid arthritis. Curr Pharm Des (2005) 0.83
Localized scleroderma and idiopathic thrombocytopenia. J Rheumatol (1981) 0.82
19S IgM rheumatoid factor-7S IgG rheumatoid factor immune complexes isolated in sera of patients with juvenile rheumatoid arthritis. Pediatr Res (1986) 0.82
Collagenous abnormalities in the heart of the tight-skin mouse. J Mol Cell Cardiol (1987) 0.82
Failure of multitarget detection of Borrelia burgdorferi-associated DNA sequences in synovial fluids of patients with juvenile rheumatoid arthritis: a cautionary note. Arthritis Rheum (1992) 0.82
Endomyocardial biopsy in patients with systemic lupus erythematosus. J Rheumatol (1988) 0.82
Screening for uveitis in juvenile rheumatoid arthritis. J Pediatr Ophthalmol Strabismus (1998) 0.81
Immune complexes and late complement proteins trigger activation of Syk tyrosine kinase in human CD4(+) T cells. Clin Exp Immunol (2012) 0.81
Assessment of digital vascular structure and function in response to bosentan in patients with systemic sclerosis-related Raynaud's phenomenon. Rheumatology (Oxford) (2006) 0.81
Specificity of hidden 19S IgM rheumatoid factor in patients with juvenile rheumatoid arthritis. Arthritis Rheum (1981) 0.81
Effects of polyarticular and pauciarticular onset juvenile rheumatoid arthritis on facial and mandibular growth. J Rheumatol (1996) 0.81
In vitro effects of methotrexate on polyamine levels in lymphocytes from rheumatoid arthritis patients. Clin Exp Rheumatol (1997) 0.81
A pilot study of acetic acid iontophoresis and ultrasound in the treatment of systemic sclerosis-related calcinosis. Rheumatology (Oxford) (2005) 0.81
Endothelial-dependent vasodilation is impaired in patients with systemic sclerosis, as assessed by low dose iontophoresis. Clin Exp Rheumatol (2003) 0.81
Adult respiratory distress syndrome associated with antiphospholipid antibody syndrome. J Rheumatol (1993) 0.80
Behçet's disease: does lack of knowledge result in under-diagnosis? Clin Exp Rheumatol (2004) 0.80
19S IgM rheumatoid factor-7S IgG rheumatoid factor immune complexes isolated in patients with rheumatoid arthritis. J Lab Clin Med (1986) 0.79
Abnormal kappa:lambda light chain ratio in circulating immune complexes as a marker for B cell activity in juvenile idiopathic arthritis. Scand J Immunol (2007) 0.79
Chlorambucil in the treatment of iridocyclitis in juvenile rheumatoid arthritis. J Rheumatol (1981) 0.79
Hidden 19S IgM rheumatoid factor in synovial fluid. J Rheumatol (1982) 0.79
Induction of invasive and degradative phenotype in normal synovial fibroblasts exposed to synovial fluid from patients with juvenile rheumatoid arthritis: role of mononuclear cell population. J Rheumatol (1997) 0.79
A beta-adrenergic agonist modulates DR alpha gene transcription via enhanced cAMP levels in a glioblastoma multiforme line. J Immunol (1989) 0.79
Ulcerative colitis-colon cancer: immunologically linked disorders? N Engl J Med (1972) 0.79
HLA antigens in black and white patients with juvenile arthritis: associations with rheumatoid factor, hidden rheumatoid factor, antinuclear antibodies, and immune complex levels. J Rheumatol (1984) 0.78
Parvovirus infection mimicking systemic lupus erythematosus. Semin Arthritis Rheum (1995) 0.78
Separation and characterization of complement-fixing immune complexes in juvenile rheumatoid arthritis patients. Rheumatol Int (1986) 0.78
Carcinoembryonic antigen in benign and malignant diseases of the digestive tract. Natl Cancer Inst Monogr (1972) 0.78
Neuronal type N calcium channels mediate norepinephrine release in isolated rabbit pulmonary artery. Pulm Pharmacol (1990) 0.78
Complement-fixing hidden rheumatoid factor in children with benign rheumatoid nodules. Arthritis Rheum (1979) 0.78
Autoantibody studies in juvenile rheumatoid arthritis. Semin Arthritis Rheum (1993) 0.78
Complement-fixing hidden rheumatoid factor in juvenile rheumatoid arthritis. Arthritis Rheum (1979) 0.78
19S IgM Forssman-type heterophile antibodies in juvenile rheumatoid arthritis. Arthritis Rheum (1980) 0.78
Correlation of antiperinuclear factor with antibodies to streptococcal cell-wall peptidoglycan-polysaccharide polymers and rheumatoid factor. Clin Exp Rheumatol (1992) 0.77
Plasma and synovial fluid as solvents for monosodium urate. Ann Rheum Dis (1981) 0.77
Precipitation of 19S IgM rheumatoid factor-IgG circulating immune complexes in patients with juvenile arthritis by polyethylene glycol and separation by immobilized protein A. Clin Exp Immunol (1984) 0.77
Dual wavelength (532 and 633 nm) laser Doppler imaging of plaque psoriasis. Br J Dermatol (2005) 0.76
Expression of macrophage markers by a population of T cells obtained from synovial fluid of a subgroup of patients with juvenile rheumatoid arthritis. J Rheumatol (1998) 0.76
Antibodies to iris and retina detected in sera from patients with juvenile rheumatoid arthritis with iridocyclitis by indirect immunofluorescence studies on human eye tissue. J Rheumatol (1989) 0.76
Juvenile spondyloarthropathies. Curr Opin Rheumatol (2000) 0.76
Early onset of pulmonary parenchymal disease associated with juvenile rheumatoid arthritis. Pediatr Pulmonol (1997) 0.76
Effect of treatment with methotrexate, hydroxychloroquine, and prednisone on lymphocyte polyamine levels in rheumatoid arthritis: correlation with the clinical response and rheumatoid factor synthesis. Clin Exp Rheumatol (1997) 0.75